We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

CE Marking Received for New HIV-1 and HCV RNA Assays

By LabMedica International staff writers
Posted on 24 Jun 2015
Print article
The sample-to-answer, automated DxN VERIS Molecular Diagnostics System
The sample-to-answer, automated DxN VERIS Molecular Diagnostics System (Photo courtesy of BECKMAN COULTER, INC - Danaher)
CE Marking has been received for real-time PCR assays for rapid, quantitative determination in human plasma of Human Immunodeficiency Virus type 1 (HIV-1) and of Hepatitis C Virus (HCV) RNA using the high-performance DxN VERIS system.

DxN VERIS HCV Assay and DxN VERIS HIV-1 Assay are the two latest additions to the growing menu of CE-marked assays for use on the DxN VERIS Molecular Diagnostics System from Beckman Coulter Diagnostics (Brea, CA, USA) allowing for rapid turnaround and a more efficient workflow.

“Beckman Coulter is committed to the ongoing development of assays for DxN VERIS and aims to rapidly expand the DxN VERIS infectious disease portfolio, delivering assays that are both cost- and time-effective,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “Tests can be up and running in 10 minutes and, with true single-sample random-access and the shortest turnaround time available, results can be delivered to physicians faster,” said Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics.

HCV RNA quantification is invaluable for assessment and monitoring of patients undergoing treatment, helping to assess patient compliance, inform response‐guided therapy, and determine sustained viral response (SVR), which corresponds to cure in over 99% of cases. DxN VERIS HCV reliably detects genotypes 1 to 6, and is calibrated to the 4th WHO International Standard for HCV (NIBSC 06/102) using the DxN VERIS technology.

Similarly, quantitative measurement of HIV-1 RNA viral load in plasma plays a vital role in prognosis, management, and treatment monitoring of infected patients. DxN VERIS HIV-1 reliably detects subtypes: Group M (A, C, D, F, G, H); Group N; Group O; CRF AE and CRF AG11, and is traceable to the WHO International Standard for HIV-1 using the DxN VERIS technology.

Short assay run-times (less than 102 minutes for DxN VERIS HCV and less than 87 minutes for DxN VERIS HIV-1) enable faster clinical decision making. Automated sample processing, amplification, and detection enable the user to simply load the sample tube onto the DxN VERIS system, subsequent steps are performed automatically. All DxN VERIS assays are supplied in a unique single-cartridge system, reducing wastage and consumable costs compared to traditional batch-plate systems.

Additional CE marked assays for the system include DxN VERIS CMV Assay (for human Cytomegalovirus in plasma) and DxN VERIS HBV Assay (for Hepatitis B Virus in plasma and serum), with many other assays under development.

Related Links:

Beckman Coulter Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.